Tredje AP fonden Sells 16,252 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tredje AP fonden cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 50.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,253 shares of the medical equipment provider’s stock after selling 16,252 shares during the period. Tredje AP fonden’s holdings in Zimmer Biomet were worth $1,717,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ZBH. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet in the fourth quarter valued at $25,000. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the third quarter valued at $28,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet in the third quarter valued at $35,000. Finally, Kentucky Trust Co bought a new stake in Zimmer Biomet in the fourth quarter valued at $39,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 2.4 %

NYSE:ZBH opened at $110.10 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The business’s 50-day moving average price is $105.83 and its two-hundred day moving average price is $107.03. The firm has a market capitalization of $21.92 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Analyst Ratings Changes

A number of brokerages have weighed in on ZBH. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.